CRISPR Therapeutics AG (CRSP) Capital Expenditures (2015 - 2026)

CRISPR Therapeutics AG has disclosed Capital Expenditures across 12 years of filings, most recently posting $504000.0 for Q1 2026.

• Capital Expenditures for Q1 2026 came in at $504000.0, up 144.66% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.2 million (up 435.73% YoY), and the FY2025 annual result was $914000.0, up 493.51% from the prior year.
• Capital Expenditures came in at $504000.0 for Q1 2026 at CRISPR Therapeutics AG, down from $517000.0 in the prior quarter.
• In the past five years, Capital Expenditures ranged from a high of $32.3 million in Q4 2022 to a low of -$20.1 million in Q3 2022.
• The 5-year median for Capital Expenditures is $707000.0 (2024), against an average of $2.8 million.
• Peak annual rise in Capital Expenditures reached 1552.97% in 2022, while the deepest fall reached 1480.85% in 2022.
• CRISPR Therapeutics AG's Capital Expenditures stood at $32.3 million in 2022, then tumbled by 97.71% to $738000.0 in 2023, then slumped by 302.3% to -$1.5 million in 2024, then surged by 134.63% to $517000.0 in 2025, then dropped by 2.51% to $504000.0 in 2026.
• The last three Capital Expenditures figures came in at $504000.0 (Q1 2026), $517000.0 (Q4 2025), and $74000.0 (Q3 2025), per Business Quant data.